# Treatment Effect According to Timing of Administration of DWP14012 40 mg

> **NCT04613895** · NA · UNKNOWN · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 186 (estimated)

## Conditions studied

- Erosive Esophagitis

## Interventions

- **DRUG:** DWP14012
- **DRUG:** DWP14012

## Key facts

- **NCT ID:** NCT04613895
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11-17
- **Primary completion:** 2021-05-30
- **Final completion:** 2021-12-30
- **Target enrollment:** 186 (ESTIMATED)
- **Last updated:** 2020-11-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04613895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04613895, "Treatment Effect According to Timing of Administration of DWP14012 40 mg". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04613895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*